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Abstract
Lung cancer specialists play an important role in designing and implementing lung cancer
screening. We aimed to describe their 1) attitudes toward low-dose lung computed tomo-
graphy (LDCT) screening, 2) current practices and experiences of LDCT screening and 3)
attitudes and opinions towards national lung cancer screening program (NLCSP). We con-
ducted a national web-based survey of pulmonologists, thoracic surgeons, medical oncolo-
gists, and radiological oncologists who are members of Korean Association for Lung Cancer
(N = 183). Almost all respondents agreed that LDCT screening increases early detection
(100%), improves survival (95.1%), and gives a good smoking cessation counseling op-
portunity (88.6%). Most were concerned about its high false positive results (79.8%) and
the subsequent negative effects. Less than half were concerned about radiation hazard
(37.2%). Overall, most (89.1%) believed that the benefits outweigh the risks and harms.
Most (79.2%) stated that they proactively recommend LDCT screening to those who are eli-
gible for the current guidelines, but the screening propensity varied considerably. The major-
ity (77.6%) agreed with the idea of NLCSP and its beneficial effect, but had concerns about
the quality control of CT devices (74.9%), quality assurance of radiologic interpretation
(63.3%), poor access to LDCT (56.3%), and difficulties in selecting eligible population using
PLOS ONE | https://doi.org/10.1371/journal.pone.0192626 February 8, 2018 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Shin DW, Chun S, Kim YI, Kim SJ, Kim
JS, Chong S, et al. (2018) A national survey of lung
cancer specialists’ views on low-dose CT screening
for lung cancer in Korea. PLoS ONE 13(2):
e0192626. https://doi.org/10.1371/journal.
pone.0192626
Editor: Peter M. A. van Ooijen, University of
Groningen, University Medical Center Groningen,
NETHERLANDS
Received: August 27, 2017
Accepted: January 26, 2018
Published: February 8, 2018
Copyright: © 2018 Shin et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This study was supported by the Korean
Ministry of Health and Welfare (HI15C0554 and
HI16C0286) for JSR. The funders had no role in
study design, data.
Competing interests: The authors have declared
that no competing interests exist.
self-report history (66.7%). Most (79.2%) thought that program need to be funded by a spe-
cialized fund rather than by the National Health Insurance. The opinions on the level of
copayment for screening varied. Our findings would be an important source for health policy
decision when considering for NLCSP in Korea.
Introduction
Lung cancer is one of the most common cancer and the leading cause of cancer deaths in
Korea, Asia, and worldwide [1]. In Korea, 24,027 new lung cancers were diagnosed in 2014,
and 17,440 died from lung cancer, accounting for 22.8% of all cancer deaths [2]. Prognosis of
lung cancer remains poor, as it is often diagnosed at an advanced stage when curative treat-
ment is no longer possible. In Korea, only 20% are diagnosed at a localized stage, and the
5-year survival rate of all lung cancer patients is only 21.9% [2]. Therefore, effective strategies
have been sought to address this important public health problem.
The National Lung Screening Trial (NLST) demonstrated 20% and 6.7% relative reductions
in lung cancer and all-cause mortality with annual low-dose computed tomography (LDCT)
screening [3]. This result in 2011 has prompted multiple organizations to announce guidelines
for lung cancer screening, including the American Cancer Society (ACS) [4], the American
Society of Clinical Oncology (ASCO), the American Association of Thoracic Surgery (AATS)
[5], the American College of Chest Physicians (ACCP)[6], and the U.S. Preventive Services
Task Force [7]. A simulation study conducted in other settings, such as in China, also pro-
duced favorable results in terms of mortality outcomes [8].
However, there is still debate on the benefits and potential harms of lung cancer screening.
Interim analyses of smaller studies showed no reduction in lung cancer mortality with LDCT
screening [9]. In addition, LDCT screening carries a risk of negative effects such as false-posi-
tive results (i.e. 90% of the nodules discovered, found in 20% of patients according to the
NLST definition and results), which increased the likelihood of receiving invasive diagnostic
procedures and repeated irradiation. Therefore, despite the recommendations of specialist
societies, the American Academy of Family Physician (AAFP) concluded that the evidence is
insufficient to recommend for or against LDCT screening based on age and smoking history
[10].
Since the Affordable Care Act that mandates private insurers to cover preventive services
with a grade A and B by the USPSTF, in the US, Medicare and private insurers have initiated
LDCT screening coverage, and LDCT is now widely adopted for lung cancer screening
[11,12]. In Korea, the national screening guideline was revised to include LDCT screening
starting September 2015, which happens to coincide with our study period. Demonstration
project for National Lung Cancer Screening Program (NLCSP) is planned from 2017.
Healthcare providers play an important role in the informed decision about cancer screen-
ing by giving guidance to the patients and their family members about the benefits, potential
harms, process, and the cost of LDCT screening. Lung cancer specialists in particular, are most
likely to play an important role in designing and implementing lung cancer screening pro-
grams, since most primary clinics do not have the resources to implement LDCT. Further-
more, the opinion of these experts is the key in forming the national strategy for lung cancer
prevention. Therefore, we aimed to describe their 1) attitudes regarding LDCT screening, 2)
current practices and experiences of LDCT screening and 3) attitudes and opinions towards
NLCSP, using a nationally representative sample of lung cancer specialists. In this particular
study, we did not seek the opinion of primary care physicians.
Attitudes towards low-dose lung CT
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Methods
Study design and subjects
The present study was conducted as a part of a national web-based survey to explore the views
of lung cancer specialists regarding the smoking-related policies in October 2015. The institu-
tional review board of the Inha University Hospital, Incheon, Korea approved this study (IRB
no. 15–053).
Among members of Korean Association for Lung Cancer, we included pulmonologists,
thoracic surgeons, medical oncologists, and radiological oncologist. We limited our partici-
pants to lung cancer specialist physicians who provide direct care to lung cancer patients and
their family, as some of our question items require a certain level of clinical interaction experi-
ence (e.g. current practice, physician-perceived reasons for refusal of lung cancer screening).
Therefore, thoracic radiologists or pathologists were not included in our study. A total of 383
physicians were identified as eligible subjects, who received up to 3 invitations to participate in
the survey with text message reminders. For non-responders, a single reminder phone call was
made to encourage participation.
Of 383 eligible subjects, 196 agreed to participate in the study (51.3% participation rate).
However, 13 of them did not provide sufficient responses to the LDCT screening question-
naire and were therefore excluded from the analysis, leading to a final sample of 183 in the cur-
rent study (47.8% effective response rate). Details of survey design are described elsewhere
[13].
Survey instrument and administration. Given the absence of a validated questionnaire
which assesses physicians’ attitudes toward LDCT screening, we developed a questionnaire
based on previous literature [12,14]. The questionnaire appraised attitudes regarding LDCT
screening [14], current practices and experiences of the specialists [14], and their attitudes and
opinions towards NLCSP [14]. In addition to the questionnaire, the survey consisted of items
measuring personal and professional demographics such as age, sex, specialty, years from
board certification, workplace (university hospital vs. specialized cancer center, private vs.
public, and geographic location), and patient volume (clinical practice sessions per week, aver-
age number of overall patients and lung cancer outpatients per week). The survey was
reviewed and piloted for content and clarity by a committee, of which member includes 12
lung cancer specialists and a public health researcher who is an expert in survey methodology.
Attitudes towards lung cancer screening with LDCT. Physicians were asked whether
they agree or disagree with the statements regarding benefits, potential harms, and cost of lung
cancer screening with LDCT on a 4-point Likert scale (strongly disagree to strongly agree).
Questions regarding benefits included early detection of lung cancer, increased survival
[10,14], smoking cessation counseling opportunities and actual resultant in smoking cessation
[15]. Questions regarding potential harms included medical and psychological consequences
of false positive results [12,14,16,17], false reassurance and continued smoking from a negative
result [2,12], and radiation hazards [12,16]. Cost burden was also asked [11,14]. Following
these questions, respondents were asked to assess the net benefit of LDCT screening, consider-
ing the potential benefits, risks, and cost.
Current lung cancer screening practices. Three clinical vignettes were used to assess cur-
rent lung cancer screening practices. Physicians were asked if they would offer LDCT screen-
ing to 1) an asymptomatic long-term smoker who meets the current eligibility criteria of the
guideline (e.g.30 pack-year and 55–79 years old) [5,7,18], 2) an asymptomatic long-term
smoker who does not meet the eligibility criteria (e.g. 20 to 30 pack-year and 40–50 years old),
3) a son of lung cancer patient who is not eligible (e.g. 10 pack-year of smoking history and has
worries about lung cancer). Response options were “proactively recommend”, “recommend
Attitudes towards low-dose lung CT
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when the patient seeks for an expert opinion”, and “not recommend”. Responses to clinical
vignettes have been shown to correlate with clinical behavior, and are also known to be a useful
tool for assessing clinical decision-making and guideline-based practice [19,20].
Regarding reimbursement and payment issue [14,16], we asked how they have their
patients get LDCT for screening. The response options were “through insurance coverage”,
“out of pocket expenses”, “through a referral to a health screening center”, and “not recom-
mend LDCT for screening purposes”.
Physicians were also asked about their experiences regarding the patients’ refusal to take
LDCT for screening upon offer. Six plausible items were provided as likely reasons for patients’
reluctance to LDCT screening, based on cancer screening literature and clinical experiences
[11,12,21]: “lack of knowledge on lung cancer risks [12,16]”, “denial of their own risk for lung
cancer [22]”, “fear of actual lung cancer detection [12,21]”, “lack of perceived benefit of early
lung cancer detection [12,21]”, “concern about the screening cost [12,16,22]”, and “conflict of
interest that doctor recommended the screening for the doctor’s own financial benefit [23]”.
Attitudes and opinions toward NLCSP. Physicians were also asked whether they think
LDCT should be part of the National Cancer Screening Program (NCSP). Expected benefits of
having LDCT screening in the NCSP were asked in terms of effectiveness, cost-effectiveness,
and equity [12,17]. Questions for perceived barriers in the implementation of LDCT screening
as a NCSP included unavailability of LDCT in primary care [12,17], quality control of the
equipment and personnel perspectives [16], selection of indicated persons, and potential for-
feit. Physicians were to answer each item on a 4-point Likert scale (strongly disagree to
strongly agree). Opinions on public funding for NLCSP were obtained by asking them whether
indicated patients should bear all or only part of the cost for screening, whether the program
should be funded and how.
Statistical analysis. Descriptive statistics were used to calculate responses provided to the
questions. All statistical analyses were performed using STATA version 14.0 (STATA corp,
College Station, TX, USA).
Results
Respondent characteristics
Most participants were male (82.0%) and practiced in a university hospital or a hospital with
cancer center (88.0%) (Table 1). Respondents were comprised of pulmonologists (59.0%), tho-
racic surgeons (23.0%), medical oncologists (10.4%), and radiation oncologists (7.7%). The
average age was 44.4 years (SD 7.2 years), and mean year from board certification was 13.6
years (SD 7.2 years).
Attitudes toward LDCT screening
Almost all physicians agreed that LDCT screening increases early detection (100%) and sur-
vival (95.1%), and most thought that it gives a good opportunity to counsel smoking cessation
(88.6%), and that it can increase the chances of smoking cessation in their patients (61.2%).
The majority of physicians believed that the risk of false positive is too high (79.8%), and that
false positive results can produce psychological distress (88.0%) and physical harms (55.2%).
Only a minority of physicians believed that false positive results would incur unnecessary tests
(16.9%).
More than half of the physicians were concerned that negative results can give false reassur-
ance (59.1%) or allow smokers to continue smoking (63.4%). Less than half believed that radia-
tion hazard is clinically meaningful (37.2%), and that the cost of screening is burdensome for
Attitudes towards low-dose lung CT
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people with an average income (40.5%). Overall, the majority of physicians (89.1%) agreed
that the LDCT screening benefits outweigh the potential risk and harms (Table 2).
Current practice and experience of LDCT screening
In response to the patient vignettes, most physicians (79.2%) indicated that they would proac-
tively recommend LDCT screening to those who are eligible according to the current guide-
lines, while others (19.7%) would recommend it when the patients seek for an expert opinion.
For a long-term smoker who does not meet the current eligible criteria, physicians stated that
they would recommend screening proactively (68.3%) or upon the patient’s request for an
expert opinion (24.0%). For a smoker whose parent(s) had been diagnosed with lung cancer,
has a 10 pack-year smoking history of his own, and worries about getting lung cancer, only
9.3% of the physicians answered that they would proactively recommend screening. Most oth-
ers (76.0%) would recommend it upon request for their opinion, while 14.8% would discour-
age screening (Table 3).
When asked about ordering LDCT for the screening eligible population, half (50.3%) of
physicians reported that they order it under insurance (30% copayment); approximately a
quarter (27.3%) order it as out-of-pocket expenses and less than a quarter (19.1%) refer
patients to health screening centers where patients get private screening at their own cost.
Physician-perceived reasons of rejecting LDCT screening among patients who are currently
indicated included concerns about cost (73.8%), denial of their own risk (67.2%), lack of per-
ceived benefit (54.1%), fear of actual lung cancer detection (53.5%), suspicion for physicians’
own benefit (48.6%), and lack of knowledge of lung cancer risk (41.6%) (Table 4).
Table 1. Characteristics of the participants (N = 183).
N or mean % or SD
Age (mean, SD) 44.4 7.2
Gender
Male 150 82.0
Female 33 18.0
Specialty
Pulmonologist 108 59.0
Thoracic surgeon 42 23.0
Medical oncologist 19 10.4
Radiation oncologist 14 7.7
Years from board certification (mean, SD) 13.6 7.2
Hospital type
University hospital 149 81.4
Cancer specialty hospital 12 6.6
Secondary hospital 13 7.1
Non-response 9 4.9
Hospital type
Public hospital 46 25.1
Private hospital 128 70.0
Non-response 9 4.9
Number of clinical sessions per week (mean, SD) 4.1 1.4
Number of lung cancer patients per week (mean, SD) 32.1 40.4
SD: standard deviation
https://doi.org/10.1371/journal.pone.0192626.t001
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Attitudes towards and opinions on NLCSP
Most physicians (77.6%) agreed with the idea of national lung cancer screening program
(NLCSP). Most respondents strongly agreed or agreed that NLCSP would reduce morality
(87.4%), will be cost-effective (83.6%) and cost-saving (68.4%), and that it would improve
health equity (77.1%). However, at the same time, majority were concerned about the quality
control of CT devices (74.9%), quality assurance of radiological interpretation (63.3%), poor
access to LDCT in primary care (56.3%). They also believed that there may be difficulties in
selecting eligible screening population because they would have to rely on self-reports on the
smoking history (66.7%), and that people may fabricate their smoking history just to become
eligible for screening (83.6%) (Table 5).
Regarding self-pay proportion of the screening cost, most physicians (77.6%) endorsed
some level of copayment, with most frequently answered proportion to be 50%. Minority phy-
sicians advocated no copayment at all (12.6%), and even less (7.7%) insisted on 100% out-of-
pocket screening for the eligible population. Majority (79.2%) agreed that the program would
need to be supported by a specialized fund, such as the Health Promotion Fund from tobacco
taxes, rather than by the National Health Insurance (Table 6).
Table 2. Attitudes toward lung cancer screening by low-dose computed tomography among lung cancer specialist physicians.
Strongly disagree Disagree Agree Strongly agree
N % N % N % N %
Potential benefits and effectiveness
Increases early detection 0 0.0 0 0.0 105 57.4 78 42.6
Improves survival by early detection 1 0.6 8 4.4 124 67.8 50 27.3
Provides opportunity for smoking cessation counseling 1 0.6 20 10.9 124 67.8 38 20.8
Increases smoking cessation 4 2.2 67 36.6 94 51.4 18 9.8
Potential harms
Risk for false positive result is too high. 1 0.6 36 19.7 114 62.3 32 17.5
False positive result incurs unnecessary further tests. 36 19.7 116 63.4 31 16.9 0 0.0
False positive result produces psychological distress. 1 0.6 21 11.5 121 66.1 40 21.9
False positive result produces physical harms. 4 2.2 78 42.6 87 47.5 14 7.7
Negative result gives false reassurance. 2 1.1 74 40.4 94 51.4 13 7.1
Negative result lead smokers to continue smoking. 4 2.2 63 34.4 107 58.5 9 4.9
Radiation hazard is clinically meaningful. 16 8.7 99 54.1 67 36.6 1 0.6
Cost
Cost is burdensome to people with an average income. 5 2.7 104 56.8 66 36.1 8 4.4
Overall evaluation
Taken all, benefits outweigh the risks. 1 0.6 19 10.4 124 67.8 39 21.3
https://doi.org/10.1371/journal.pone.0192626.t002
Table 3. Current practice of lung cancer screening recommendation among lung cancer specialist physicians.
Proactively
recommend
Recommend
when the
patient seeks
opinion
Do not
recommend
Clinical scenarios N % N % N %
Smoking history30 pack-year & age 55 to 79 years (indicated for lung cancer screening by current guidelines) 145 79.2 36 19.7 2 1.1
Smoking history 20 to 30 pack-year & age 40 to 59 years (not indicated for lung cancer screening by current guidelines) 44 24.0 125 68.3 14 7.7
Smoking history 10 pack-year, son of lung cancer patient and worries about lung cancer 17 9.3 139 76.0 27 14.8
https://doi.org/10.1371/journal.pone.0192626.t003
Attitudes towards low-dose lung CT
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Discussion
To our knowledge, this is the first results of a national survey of lung cancer specialist physi-
cians’ attitudes toward and current practice of LDCT screening for lung cancer. Timely inves-
tigation of an emerging health issue, use of a nationwide sample covering all geographic areas,
specialty and types of hospital are unique strengths of this study.
Attitudes towards lung cancer screening by low-dose CT
Physician knowledge and attitude towards LDCT screening is important as it can determine
their recommendation, which is critical for patient’s uptake or actual ordering of LDCT
screening [11,12,14]. Overall, nearly 90% of our study participants agreed that benefits of
LDCT screening for guideline-eligible population outweigh the potential risks, showing their
generally positive attitudes.
Our study participants strongly believed that LDCT is effective in early detection of cancer
and improving survival. In fact, recent evidence showed that lung cancer screening with
LDCT is more effective than breast or colorectal cancer screening (number needed to treat 320
vs. 1339 and 871, respectively) [12]. Lung cancer specialists seem to acknowledge such benefits,
contrary to primary care physicians who were generally skeptical about LDCT screening [16].
Table 4. Physician-perceived reasons for refusal of lung cancer screening among people who are indicated.
Frequently Often Rarely Never
N % N % N % N %
Lack of knowledge of lung cancer risks (e.g. does not know that smoking increases lung cancer risk) 8 4.4 68 37.2 86 47.0 21 11.5
Denial of their own lung cancer risk (e.g. knows that smoking increases lung cancer risk, but think he/
she will be OK)
16 8.7 107 58.5 52 28.4 8 4.4
Fear of actual lung cancer detection (e.g. fear that lung cancer will be detected by screening) 7 3.8 91 49.7 73 39.9 12 6.6
Lack of perceived benefit of early lung cancer detection (e.g. thinks that he/she will die anyway once he/
she gets lung cancer)
15 8.2 84 45.9 72 39.3 12 6.6
Concern about the cost 43 23.5 92 50.3 44 24.0 4 2.2
Suspicion that doctors recommend screening for their own good 13 7.1 76 41.5 80 43.7 14 7.7
https://doi.org/10.1371/journal.pone.0192626.t004
Table 5. Attitudes towards national lung cancer screening program (NLCSP) among lung cancer specialist physicians.
Strongly disagree Disagree Agree Strongly agree
N % N % N % N %
Expected benefit
NLCSP will reduce mortality from lung cancer. 0 0.0 21 11.5 119 65.0 41 22.4
NLCSP will be a cost-effective program. 0 0.0 28 15.3 119 65.0 34 18.6
NLCSP will be cost-saving. 1 0.6 55 30.1 96 52.5 29 15.9
As smoking is disproportionally prevalent in low income bracket, providing
NLCSP would be beneficial to reduce health inequality.
2 1.1 38 20.8 124 67.8 17 9.3
Potential Barriers
Access to LDCT will be not good as primary care facilities do not have the
resources.
3 1.6 75 41.0 92 50.3 11 6.0
Quality control will be an issue as the quality of CT device varies in each facility. 3 1.6 41 22.4 112 61.2 25 13.7
Quality assurance will be not easy as the quality of radiologic interpretation will
vary among radiologists.
2 1.1 45 24.6 109 59.6 25 13.7
Selecting indicated patients will be not easy as the smoking history (duration &
amount) is obtained self-reportedly.
3 1.6 56 30.6 110 60.1 12 6.6
People may fabricate their smoking history to get lung cancer screening if
NLCSP become available.
1 0.6 27 14.8 129 70.5 24 13.1
https://doi.org/10.1371/journal.pone.0192626.t005
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According to NLST data, around 30% of people who underwent LDCT screening had at
least one false positive result, and 0.3% will have a major complication from a following inva-
sive diagnostic procedure [18]. While lung cancer specialists generally acknowledged the high
risk of false positive results and the possible subsequent psychological and physical harms, they
did not think it incurred further unnecessary tests. It can be interpreted that even though
some patients may experience negative consequences from false positive results, lung cancer
specialists generally think that follow-up or further diagnostic tests is still worthwhile and not
‘unnecessary’. This is also in contrast with the views of primary care physicians who are often
concerned about false-positive results and their downstream consequences, such as further
diagnostic testing and invasive procedures, psychological stress, missing work, and financial
issues as well [16]. More recently published NELSON or UKLS trials have used a different defi-
nition of false positive: requirement for referral to the pulmonologist and further diagnostic
investigation (around 3.5%) without subsequent diagnosis of lung cancer [24,25], unlike
NLST, in which every individual who had an additional CT scan before a repeat annual screen
was considered positive. This such interpretation of the term false-positive may potentially
attenuate the perceived harms coming from false-positive results. Furthermore, the advent of
volumetric analysis of detected nodules would be able to actually reduce the harms related to
false positive results, relieving the physicians’ concerns [25,26].
Integrated smoking cessation services to lung cancer screening was emphasized to take
the opportunity of ‘teachable moment’ and improve cost-effectiveness of the LDCT screening
program [15,22,27]. While most agreed that discussing LDCT screening provides a
Table 6. Opinions on the public funding of national lung cancer screening program among lung cancer specialist
physicians.
N %
Appropriate amount of out-of-pocket payment for the NLCSP
Free of charge 23 12.6
Copayment (appropriate level of copayment: ________ %) 146 77.6
5% 6 3.3
10% 23 12.6
15% 1 0.6
20% 23 12.6
25% 1 0.6
30% 23 12.6
40% 2 1.1
45% 2 1.1
50% 60 32.8
60% 1 0.6
Missing 4 2.2
100% out-of-pocket 14 7.7
Non-response 4 2.2
Appropriate public funding methods for the NLCSP
General budget (national, regional0 3 1.6
National Health insurance (insurance premium) 22 12.0
Specialized fund (e.g., Health promotion fund from tobacco tax) 145 79.2
Out-of-pocket cost 11 6.0
Non-response 2 1.1
CT: computed tomography
https://doi.org/10.1371/journal.pone.0192626.t006
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good opportunity for smoking cessation counseling, some of them were skeptical about whether
it actually improves smoking cessation. This might be linked to the perceived-harm of false neg-
ative result; more than half of the participants agreed that patients can be falsely reassured about
their health and continue smoking. Currently, evidence is scarce and contradictory whether a
negative screening test will decrease risk perception or provide false reassurance, and whether
LDCT screening, either by itself or combined with smoking cessation services, has a positive
effect on smoking behaviors [15,28]. Further research will be needed to find out an optimal
method of integrating smoking cessation services in the upcoming NLCSPs.
Around two-thirds disagreed that radiation hazard is clinically meaningful, and this is con-
cordant with the recent analyses that radiation exposure and cancer risk from LDCT screening
is acceptable, even if non-negligible, considering the substantial effectiveness of mortality
reduction [29]. Regarding cost, approximately 40% agreed that cost for LDCT screening is
burdensome to people with an average salary.
Current practice
Virtually all lung cancer specialists answered that they recommend LDCT screening to the
guideline-eligible patient, suggesting that they are familiar with the current lung cancer screen-
ing guidelines. While 20% did so only when patients seek expert opinions, this might be
because there is currently no established lung cancer screening program in Korea and the cost
is generally paid out-of-pocket. This is contrary to the US primary care providers who were
more cautious and ambivalent about offering LDCT screening, preferring to take a “wait and
see” approach [16].
Vast majority also answered that they would recommend LDCT screening to the long-term
smoker who did not meet the current criteria, and to the son of lung cancer patient, either pro-
actively or when asked for their opinions. This largely reflects the positive attitudes of our
study participants toward LDCT screening in terms of effectiveness and cost-effectiveness.
This is also closely related to the fee-for-service healthcare system in Korea where patients’
request is an important motive for preventive services [14]. Several guidelines have expanded
the eligibility criteria to include individuals who are50 years and have 20 pack-year smok-
ing history or have an additional risk factor such as lung cancer family history [5,30]. However,
such practice could raise the issue of over-screening. Extrapolation of the current recommen-
dations to less high risk groups should be done with extreme caution, as its effectiveness and
cost-effectiveness would be lower than in the higher risk group that is currently guideline-eligi-
ble. It would incur substantial cost implications as well, not only from the screening itself but
also from consequent tests and procedures after a positive screening result [31,32]. Additional
effort is warranted to establish effectiveness and cost-effectiveness results pertinent to Korea,
to facilitate a shared decision making on lung cancer screening.
Without established national screening program or reimbursement guidelines, there was
much variation in the prescription pattern. Half of our study participants prescribed LDCT
under insurance (probably with some diagnostic code for reimbursement) and the other half
100% out-of-pocket. There is a need for reasonable criteria to reduce the variation.
Lack of knowledge of screening benefit, risk denial and cost burden are the common barri-
ers of screening practice; it should be addressed in the national policy to implement and dis-
seminate LDCT screening.
Attitudes and opinions towards NLCSP
In the US, screening for lung cancer with LDCT is estimated to cost $81,000 per quality-
adjusted life year gained [32], and implementation of LDCT screening program on a
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nationwide scale was estimated to cost $1.3~2.0 billion annually [33]. To our knowledge, there
has not been a formal estimation in Korea on LDCT screening. However, lung cancer special-
ists, consistent with their attitudes toward LDCT screening itself, generally had a positive view
on the cost-effectiveness of the NLCSP. This is in contrast to that of US primary care physi-
cians, who had ethical concerns about allocating limited healthcare resources to LDCT screen-
ing rather than to other tobacco control programs, or to older, heavy smokers rather than
young population who are likely to result in greater social benefit [16].
Our respondents generally agreed on the positive impact on health equity, as smoking is
more prevalent in the lower social class. Previous studies have shown discrepant views on
implementation of NLCSP in terms of health equity: some argued that it would improve equity
as underprivileged people are often excluded from latest advances, while others thought it
could burden patients who cannot afford follow-up care [16]. Further study is warranted to
provide empirical data on the impact of NLCSP on health equity issues.
Respondents had concerns about infrastructure for NLCSP, such as proper access to the
program and assuring high quality screening in terms of equipment and personnel. A US
study found that many primary care physicians were not sure about whether LDCT is available
near their practice and whether it is covered by Medicare/Medicaid, and therefore did not
refer their high risk patients for screening [17]. High quality of device and accurate radiologic
interpretation are essential to ensure screening benefit and to reduce potential harms. Current
guidelines recommend that lung cancer screening should only be performed according to a
standard protocol at centers that are able to guarantee rigorous quality control, and should be
linked to multidisciplinary management team with well-developed program of minimally
invasive thoracic surgery [26,34,35]. Therefore, quality control plan should be an important
consideration in the implementation and dissemination of the NLCSP. Financing the NLCSP
is another important issue in the implementation of NLCSP. Cost burden was the most fre-
quently cited barrier to LDCT screening in our study, which is consistent with the US findings
that few patients are willing to pay out of pocket [12]. Respondents had varying opinions on
the level of copayment. While most agreed on the need for copayment, there was no universal
agreement on the proportion of copayment. Others either advocated free screening or insisted
100% out-of-pocket service. However, when it came to public funding for the NLCSP, most
advocated using a specialized fund from tobacco taxes. This might be due to a societal concern
that non-smokers would be paying premiums for smokers to receive screening, which was
mentioned in a previous US study [16].
Limitations
One notable limitation of our study is that we surveyed lung cancer specialists only. Thoracic
radiologists or pathologists were not included. Most guideline-eligible long-term smokers do
not come in direct contact with lung cancer specialists, but are more likely meet with primary
care physicians for healthcare including health checkup or care of chronic illnesses, such as
hypertension or diabetes. Future study is warranted to investigate the views of primary care
physicians in Korea. However, the attitudes of lung cancer specialists are particularly impor-
tant as they can influence the clinical practice guidelines, and primary care physicians adopt
and implement such guidelines in their practice [16]. Other potential limitation is a relatively
small sample size and a low response rate, which can create nonresponse bias. In addition,
although the survey items were developed mainly by adopting items used in previous studies,
the questionnaire was neither guided by a theoretical framework nor validated psychometri-
cally. Finally, our study findings need to be interpreted in the Korean context, and the gener-
alizability to other countries are limited because of the differences in culture and health care
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system. However, the lung cancer specialists’ view on the potential benefit, harm, and barriers
of lung cancer screening identified from this study would help the policy makers from other
countries when planning their own program.
Conclusions
Our results demonstrated that most Korean lung cancer specialists are positive about LDCT
screening, recommend LDCT screening concordant with the current guideline, but also find
difficulties with patients’ refusal for various reasons. They are also generally positive about the
national lung cancer screening program, but have concerns about access, quality control, and
objective selection of the eligible patients using self-reported smoking history. Decision for
implementing NLCSP should be made in the broader context of overall benefits, risks, and
cost for screening program. Healthcare system should carefully plan and allocate sufficient
resources to ensure success of an organized screening program. Our findings from this study
on the attitudes of lung cancer specialists on NLCSP would be an important source for future
health policy decision.
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